http://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. Researchers at Mayo Clinic Cancer Center have developed new guidelines to treat recently diagnosed multiple myeloma patients who are not participating in clinical trials. The guidelines give physicians practical, easy to follow recommendations for providing initial therapy, stem cell transplant and maintenance therapy. The guidelines are published in the current issue of the journal Mayo Clinic Proceedings and represent a consensus opinion of hematologists at Mayo Clinic Cancer Center sites in Minnesota, Florida and Arizona. http://medicalxpress.com/news/2013-04-multiple-myeloma-treatment-guidelines-personalize.html Cancer Mon, 01 Apr 2013 12:23:08 EST news284037777 Researchers at Moffitt Cancer Center and colleagues have investigated the safety, efficacy and the maximum tolerated dose of pomalidomide for patients with multiple myeloma who have disease relapsed after treatments with other drugs, such as bortezomib and lenalidomide. This phase I clinical trial enrolled 38 patients, and pomalidomide provided a minimal or better response for 42 percent of the patients, a partial response or better for 21 percent, and a complete response for 3 percent. http://medicalxpress.com/news/2013-01-drug-survival-multiple-myeloma-relapse.html Cancer Thu, 24 Jan 2013 04:00:10 EST news278222362 Although rare there are several treatments available for cutaneus lupus erythematosus (CLE). However other options are needed for people who do not respond to medication or relapse. A new study into the thalidomide derivative lenalidomide, published today in BioMed Central's open access journal Arthritis Research & Therapy, shows that treatment with lenalidomide is safe, with patients seeing an improvement in as little as two weeks. http://medicalxpress.com/news/2012-12-lenalidomide-effective-alternative-treatment-cutaneus.html Cancer Fri, 07 Dec 2012 02:27:46 EST news274069511 A novel therapy in the early stages of development at Virginia Commonwealth University Massey Cancer Center shows promise in providing lasting protection against the progression of multiple myeloma following a stem cell transplant by making the cancer cells easier targets for the immune system. http://medicalxpress.com/news/2012-10-harness-immune-stem-cell-transplant.html Immunology Mon, 01 Oct 2012 16:04:31 EST news268326194 Multiple myeloma patients are better equipped to halt progression of this blood cancer if treated with lenalidomide, or Revlimid, following a stem cell transplant, according to a study co-authored by a physician with the Oregon Health & Science University Knight Cancer Institute. http://medicalxpress.com/news/2012-05-lenalidomide-prolongs-disease-multiple-myeloma.html Cancer Wed, 16 May 2012 09:21:14 EST news256378867 Multiple myeloma is a form of cancer where the plasma cells in the bone marrow grow out of control, causing damage to bones as well as predisposing patients to anemia, infection and kidney failure. A medical procedure called autologous hematopoietic stem cell transplantation, commonly known as a stem cell transplant, is frequently an important treatment option for many patients. http://medicalxpress.com/news/2012-05-benefit-maintenance-therapy-multiple-myeloma.html Cancer Fri, 11 May 2012 15:13:34 EST news255968004 (HealthDay) -- Three new studies confirm that the drug lenalidomide can significantly lengthen the time that people with multiple myeloma experience no worsening of their disease, either after having a stem cell transplant or getting chemotherapy. http://medicalxpress.com/news/2012-05-drug-myeloma-patients.html Cancer Wed, 09 May 2012 20:50:01 EST news255805953 (HealthDay) -- For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according to a study published online April 30 in the Journal of Clinical Oncology. http://medicalxpress.com/news/2012-05-chemo-combination-multiple-myeloma.html Cancer Wed, 02 May 2012 15:30:01 EST news255188297 Research on the same protein that was a primary mediator of the birth defects caused by thalidomide now holds hope in the battle against multiple myeloma, says the study's senior investigator, Keith Stewart, M.B., Ch.B. of Mayo Clinic in Arizona. Dr. Stewart presented the results at the 53rd annual meeting of the American Society of Hematology in San Diego. http://medicalxpress.com/news/2011-12-patients-immunomodulator-therapy-multiple-myeloma.html Cancer Sun, 11 Dec 2011 11:00:01 EST news242798969 (Medical Xpress) -- A three-drug combination treatment for the blood cancer multiple myeloma compares favorably to the best established therapy for newly diagnosed patients, according to a multi-center study led by Andrzej Jakubowiak, MD, PhD, professor of medicine and director of the multiple myeloma program at the University of Chicago Medical Center. http://medicalxpress.com/news/2011-12-drug-combination-highly-effective-newly.html Cancer Thu, 08 Dec 2011 06:00:01 EST news242545705 An early phase multiple myeloma trial has unexpectedly revealed that the drug lenalidomide interacts with another protein in cells that affect its dose level in the body, say researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) who conducted the study. http://medicalxpress.com/news/2011-08-urges-caution-lenalidomide-dosage.html Medications Mon, 08 Aug 2011 16:50:01 EST news232031108